Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025)

Telix Pharmaceuticals has reported Intangibles over the past 3 years, most recently at $592.8 million for Q4 2025.

  • Quarterly Intangibles rose 117.84% to $592.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $592.8 million through Dec 2025, up 117.84% year-over-year, with the annual reading at $592.8 million for FY2025, 129.9% up from the prior year.
  • Intangibles was $592.8 million for Q4 2025 at Telix Pharmaceuticals, up from $272.1 million in the prior quarter.
  • Over five years, Intangibles peaked at $592.8 million in Q4 2025 and troughed at $71.4 million in Q4 2023.
  • The 3-year median for Intangibles is $272.1 million (2024), against an average of $312.1 million.
  • Year-over-year, Intangibles surged 281.2% in 2024 and then surged 117.84% in 2025.
  • A 3-year view of Intangibles shows it stood at $71.4 million in 2023, then surged by 281.2% to $272.1 million in 2024, then surged by 117.84% to $592.8 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Intangibles are $592.8 million (Q4 2025), $272.1 million (Q4 2024), and $71.4 million (Q4 2023).